Recombinant Human Semaphorin 4D Fc Chimera Protein, CF
Recombinant Human Semaphorin 4D Fc Chimera Protein, CF Summary
|Human Semaphorin 4D
Accession # Q92854
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.|
|Reconstitution||Reconstitute at 250 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Background: Semaphorin 4D/CD100
Semaphorin 4D (Sema4D/CD100, previously Sem J, G or C-like 2) is a 150 kDa type I transmembrane glycoprotein that belongs to the Class 4 family of transmembrane immune and nervous system semaphorins (1‑3). The human Sema4D cDNA encodes 862 amino acids (aa) that include a 21 aa signal sequence, a 713 aa extracellular domain (ECD), a 21 aa transmembrane segment and a 107 aa cytoplasmic tail. The Sema4D ECD contains one sema, PSI and immunoglobulin‑like domain, and over the full ECD (aa 22‑734), human Sema4D shares 85%, 85%, 86% and 80% aa sequence identity with mouse, rat, porcine and canine Sema4D ECDs, respectively. Sema4D is active as a homodimer that utilizes both a membrane‑proximal intermolecular disulfide bond and two hydrophobic interactions involving Phe244 and Phe246 (4, 5). Proteolysis by metalloproteinases such as TACE/ADAM17 and MMP-14 (MT1‑MMP) produce a soluble, active 120 kDa form that may also exist as a dimer (5‑7). Sema4D, produced by T cells, activated B cells and dendritic cells acts through a low affinity receptor termed CD72 in the immune system (1, 2). Unligated CD72 inhibits antigen presenting cells that express it, and this inhibition is relieved by Sema4D binding (8). Sema4D thus causes enhanced B cell survival, differentiation of macrophages and DC, and enhanced T cell antigen priming (2, 8, 9). In the CNS, Sema4D and a high affinity receptor Plexin B1 are expressed in complimentary patterns in several regions of the brain, and their interaction assists in the guidance of developing neurons (10). Intermediate affinity Sema4D:Plexin B2 binding also occurs during development, and enhances both radial and tangential neuronal migration (11). In cancer, Sema4D can also be produced by tumor‑associated macrophages, and bind to endothelial cell Plexin B1, thus promoting tumor angiogenesis (3, 6, 7, 12). While this suggests facilitation of the metastatic process, it is also recognized that semaphorins in general show both tumor promoter and suppressor functions (13, 14). For Sema4D, this is reflected in its ability to inhibit ovarian carcinoma cell survival. Finally, receptors that associate in cis with plexins, such as Met and ErbB2, are known to alter Sema4D‑mediated activities (3).
- Furuyama, T. et al. (1996) J. Biol. Chem. 271:33376.
- Kumanogoh, A. and H. Kikutani (2004) Cell. Mol. Life Sci. 61:292.
- Ch’ng, E.S. and A. Kumanogoh (2010) Mol. Cancer 9:251.
- Janssen, B.J.C. et al. (2010) Nature 467:1118.
- Elhabazi, A. et al. (2001) J. Immunol. 166:4341.
- Zhu, L. et al. (2007) Proc. Natl. Acad. Sci. USA 104:1621.
- Basile, J.R. et al. (2007) J. Biol. Chem. 282:6899.
- Kumanogoh, A. et al. (2005) Int. Immunol. 17:1277.
- Ishida, I. et al. (2003) Int. Immunol. 15:1027.
- Worzfield, T. et al. (2004) Eur. J. Neurosci. 19:2622.
- Hirschberg, A. et al. (2010) Mol. Cell. Biol. 30:764.
- Sierra, J.R. et al. (2008) J. Exp. Med. 205:1673.
- Ye, S. et al. (2010) BMC Cancer 10:611.
- Lu, T-P. et al. (2012) Transl. Cancer Res. 1:74.
Citation for Recombinant Human Semaphorin 4D Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma
Authors: M Stromecki, N Tatari, LC Morrison, R Kaur, J Zagozewski, G Palidwor, V Ramaswamy, P Skowron, M Wölfl, T Milde, MR Del Bigio, MD Taylor, TE Werbowetsk
Mol Oncol, 2018;12(4):495-513.
Sample Types: Whole Cells
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human Semaphorin 4D Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Semaphorin 4D Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human Semaphorin 4D Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image